356 related articles for article (PubMed ID: 3455806)
21. A comparative study of serum alpha-beta A immunoreactive inhibin and tumor-associated antigens CA125 and CEA in ovarian cancer.
Phocas I; Sarandakou A; Sikiotis K; Rizos D; Kalambokis D; Zourlas PA
Anticancer Res; 1996; 16(6B):3827-31. PubMed ID: 9042265
[TBL] [Abstract][Full Text] [Related]
22. Soluble urokinase plasminogen activator receptor in preoperatively obtained plasma from patients with gynecological cancer or benign gynecological diseases.
Riisbro R; Stephens RW; Brünner N; Christensen IJ; Nielsen HJ; Heilmann L; von Tempelhoff GF
Gynecol Oncol; 2001 Sep; 82(3):523-31. PubMed ID: 11520150
[TBL] [Abstract][Full Text] [Related]
23. [Clinical significance of serum sialyl Tn antigen in patients with gynecological cancer. STN Study Group].
Noda K; Shiota M; Tanizawa O; Inoue M; Tenjin Y; Sugishita T; Yakushiji M; Miyoshi T; Nozawa S; Sakuma T
Gan To Kagaku Ryoho; 1991 Jul; 18(8):1287-96. PubMed ID: 2069400
[TBL] [Abstract][Full Text] [Related]
24. [Diagnostic usefulness and limitation of measuring pancreatic cancer associate antigen, SPan-1, in patients with pancreatic cancer].
Satake K; Chung YS; Umeyama K; Takeuchi T; Kim YS
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-1):1139-46. PubMed ID: 2730018
[TBL] [Abstract][Full Text] [Related]
25. Is there a correlation between tumor marker panel and tumor size and histopathology in well staged patients with borderline ovarian tumors?
Ayhan A; Guven S; Guven ES; Kucukali T
Acta Obstet Gynecol Scand; 2007; 86(4):484-90. PubMed ID: 17486473
[TBL] [Abstract][Full Text] [Related]
26. [Relationship between serum levels and immunohistological tissue levels of CA 125 and CEA in epithelial ovarian cancers: its implications for tumor cell type specificity].
Oishi T; Maruo T; Iwasaki M; Mochizuki M
Nihon Sanka Fujinka Gakkai Zasshi; 1986 Sep; 38(9):1595-604. PubMed ID: 3464659
[TBL] [Abstract][Full Text] [Related]
27. [Detection of CA-125 antigen (non-mucinous ovarian cancer antigen)-- in serum of patients with gynecological malignancies].
Sakamoto S; Kawana H; Shimizu K; Ishihara T; Ueda K; Usman SM; Uchida S; Kawagoe K; Kihara K; Kubo H
Nihon Sanka Fujinka Gakkai Zasshi; 1984 Aug; 36(8):1261-2. PubMed ID: 6595322
[No Abstract] [Full Text] [Related]
28. Significance of some tumor markers in differential diagnosis of ovarian tumor.
Zakrzewska I; Borawska R; Poznański J; Maćkowiak B
Rocz Akad Med Bialymst; 1999; 44():235-43. PubMed ID: 10697438
[TBL] [Abstract][Full Text] [Related]
29. Clinical evaluation of tumor-associated mucin-type glycoprotein CA 54/61 in ovarian cancers: comparison with CA 125.
Suzuki M; Sekiguchi I; Tamada T
Obstet Gynecol; 1990 Sep; 76(3 Pt 1):422-7. PubMed ID: 2381620
[TBL] [Abstract][Full Text] [Related]
30. CA54/61 as a marker for epithelial ovarian cancer.
Nozawa S; Aoki D; Yajima M; Tsukazaki K; Kobayashi T; Kimura E; Terashima Y; Inaba N; Takamizawa H; Negishi Y
Cancer Res; 1992 Mar; 52(5):1205-9. PubMed ID: 1737381
[TBL] [Abstract][Full Text] [Related]
31. Measurement of a monoclonal-antibody-defined antigen (90K) in the sera of patients with ovarian cancer.
Scambia G; Panici PB; Baiocchi G; Perrone L; Iacobelli S; Mancuso S
Anticancer Res; 1988; 8(4):761-4. PubMed ID: 3178164
[TBL] [Abstract][Full Text] [Related]
32. Clinical value of sialyl Tn antigen in patients with gynecologic tumors.
Inoue M; Ogawa H; Nakanishi K; Tanizawa O; Karino K; Endo J
Obstet Gynecol; 1990 Jun; 75(6):1032-6. PubMed ID: 2342728
[TBL] [Abstract][Full Text] [Related]
33. A novel tumor-associated antigen expressed in human uterine and ovarian carcinomas.
Sonoda K; Nakashima M; Kaku T; Kamura T; Nakano H; Watanabe T
Cancer; 1996 Apr; 77(8):1501-9. PubMed ID: 8608535
[TBL] [Abstract][Full Text] [Related]
34. [Levels of circulating tumor-associated glycoprotein (TAG-72) in patients with carcinoma using a novel tumor marker, CA 72-4].
Ohuchi N; Matoba N; Taira Y; Takahashi K; Sakai N; Sato K; Fujita N; Mochizuki F; Nishihira T; Mori S
Gan To Kagaku Ryoho; 1988 Sep; 15(9):2767-72. PubMed ID: 3166366
[TBL] [Abstract][Full Text] [Related]
35. [The clinical significance of CA125 in patients with gynecological tumors--a comparative study on CA125 and other tumor markers].
Suzumori K; Yasui Y; Asai H; Hisaoka T; Mizuno K; Yagami Y
Gan No Rinsho; 1985 May; 31(5):544-8. PubMed ID: 3860666
[TBL] [Abstract][Full Text] [Related]
36. [Clinical significance of galactosyltransferase associated with tumor (GAT), a new tumor marker for ovarian cancer--with special reference to the discrimination between ovarian cancer and endometriosis].
Nozawa S; Udagawa Y; Ito K; Nishimura H; Yakushiji M; Shiota M; Noda K; Yajima M; Ohkura H; Murae M
Gan To Kagaku Ryoho; 1994 Mar; 21(4):507-16. PubMed ID: 8129392
[TBL] [Abstract][Full Text] [Related]
37. Significance of the tumour markers CA 125 II, CA 72-4, CASA and CYFRA 21-1 in ovarian carcinoma.
Hasholzner U; Baumgartner L; Stieber P; Meier W; Hofmann K; Fateh-Moghadam A
Anticancer Res; 1994; 14(6B):2743-6. PubMed ID: 7532929
[TBL] [Abstract][Full Text] [Related]
38. [Serum sialyl Tn antigen as a prognostic marker in patients with epithelial ovarian cancer].
Kobayashi H; Terao T; Kawashima Y
Nihon Sanka Fujinka Gakkai Zasshi; 1992 Jan; 44(1):14-20. PubMed ID: 1541859
[TBL] [Abstract][Full Text] [Related]
39. [The value of CA 125 determination in the serum of patients with ovarian cancer].
Bartel U; Johannsen B; Elling D
Zentralbl Gynakol; 1989; 111(5):301-9. PubMed ID: 2728673
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of CA 125 levels in differentiating malignant from benign tumors in patients with pelvic masses.
Chen DX; Schwartz PE; Li XG; Yang Z
Obstet Gynecol; 1988 Jul; 72(1):23-7. PubMed ID: 3164105
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
